1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), NIH. The ReVAMPP network conducts research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies.
The network focuses on virus families with known pandemic potential, aiming to fill key knowledge gaps and identify strategies to develop safe and effective medical countermeasures before a critical need arises.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute of Allergy and Infectious Diseases (NIAID), NIH” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Research institutions and universities are eligible, as evidenced by initial recipients including the Albert Einstein College of Medicine, Research Triangle Institute, Vanderbilt University Medical Center, and Washington University in St. Louis. Confirm the full requirements in the official notice before applying.
The current listing shows approximately $100 million per year (pending funds). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) is funded by National Institute of Allergy and Infectious Diseases (NIAID), NIH. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Washington. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Breaking Barriers: Integrating Immunology and Neuroscience to Transform AD/ADRD Research and Bring a Better Understanding of the Aging Brain is sponsored by National Institute on Aging (NIA), NIH; National Institute of Allergy and Infectious Diseases (NIAID), NIH; National Institute of Environmental Health Sciences (NIEHS), NIH. This highlighted topic encourages interdisciplinary, investigator-initiated research that integrates immunology, neuroscience, and biogerontology to advance the prevention, treatment, and potential cure of Alzheimer's disease (AD) and Alzheimer's Disease-Related Dementias (ADRD).
Global Infectious Disease Research Administration Development Award for Low- and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), NIH. This funding opportunity invites applications from research institutions in low- to middle-income countries (LMIC), including those in Africa, to provide senior administrators with advanced training in managing NIH grants.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
NIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read articleNIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read article